Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC